Protalix Biotherapeutics Stock Profit Margin
| PLX Stock | USD 1.18 0.03 2.61% |
Protalix Biotherapeutics fundamentals help investors to digest information that contributes to Protalix Biotherapeutics' financial success or failures. It also enables traders to predict the movement of Protalix Stock. The fundamental analysis module provides a way to measure Protalix Biotherapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Protalix Biotherapeutics stock.
| Last Reported | Projected for Next Year | ||
| Net Profit Margin | 0.13 | 0.13 |
Protalix | Profit Margin |
Protalix Biotherapeutics Company Profit Margin Analysis
Protalix Biotherapeutics' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Protalix Biotherapeutics Profit Margin | 0.13 % |
Most of Protalix Biotherapeutics' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Protalix Biotherapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Protalix Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Protalix Biotherapeutics is extremely important. It helps to project a fair market value of Protalix Stock properly, considering its historical fundamentals such as Profit Margin. Since Protalix Biotherapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Protalix Biotherapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Protalix Biotherapeutics' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Protalix Pretax Profit Margin
Pretax Profit Margin |
|
Based on the latest financial disclosure, Protalix Biotherapeutics has a Profit Margin of 0.1269%. This is 101.13% lower than that of the Biotechnology sector and 100.55% lower than that of the Health Care industry. The profit margin for all United States stocks is 109.99% lower than that of the firm.
Protalix Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Protalix Biotherapeutics' direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Protalix Biotherapeutics could also be used in its relative valuation, which is a method of valuing Protalix Biotherapeutics by comparing valuation metrics of similar companies.Protalix Biotherapeutics is currently under evaluation in profit margin category among related companies.
Protalix Biotherapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Protalix Biotherapeutics from analyzing Protalix Biotherapeutics' financial statements. These drivers represent accounts that assess Protalix Biotherapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Protalix Biotherapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 48.7M | 105.8M | 36.7M | 66.4M | 120.2M | 114.2M | |
| Enterprise Value | 91.8M | 151.9M | 31.2M | 82.8M | 122.8M | 116.7M |
Protalix Fundamentals
| Return On Equity | 0.73 | ||||
| Return On Asset | 0.0933 | ||||
| Profit Margin | 0.13 % | ||||
| Operating Margin | (0.54) % | ||||
| Current Valuation | 67.92 M | ||||
| Shares Outstanding | 73.05 M | ||||
| Shares Owned By Insiders | 9.76 % | ||||
| Shares Owned By Institutions | 13.90 % | ||||
| Number Of Shares Shorted | 6.46 M | ||||
| Price To Earning | (1.23) X | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 1.32 X | ||||
| Revenue | 65.49 M | ||||
| Gross Profit | 28.05 M | ||||
| EBITDA | 11.65 M | ||||
| Net Income | 8.31 M | ||||
| Cash And Equivalents | 17.11 M | ||||
| Cash Per Share | 0.41 X | ||||
| Total Debt | 26.28 M | ||||
| Current Ratio | 1.33 X | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (1.32 M) | ||||
| Short Ratio | 15.22 X | ||||
| Earnings Per Share | 0.09 X | ||||
| Price To Earnings To Growth | (0.10) X | ||||
| Target Price | 13.0 | ||||
| Number Of Employees | 208 | ||||
| Beta | 0.89 | ||||
| Market Capitalization | 86.2 M | ||||
| Total Asset | 84.43 M | ||||
| Retained Earnings | (381.55 M) | ||||
| Working Capital | 24.4 M | ||||
| Current Asset | 59.65 M | ||||
| Current Liabilities | 10.33 M | ||||
| Net Asset | 84.43 M |
About Protalix Biotherapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Protalix Biotherapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Protalix Biotherapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Protalix Biotherapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protalix Biotherapeutics using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Protalix Biotherapeutics Piotroski F Score and Protalix Biotherapeutics Altman Z Score analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Complementary Tools for Protalix Stock analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |
Is Protalix Biotherapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protalix Biotherapeutics. If investors know Protalix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protalix Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.39) | Earnings Share 0.09 | Revenue Per Share 0.97 | Quarterly Revenue Growth 0.217 | Return On Assets 0.0933 |
The market value of Protalix Biotherapeutics is measured differently than its book value, which is the value of Protalix that is recorded on the company's balance sheet. Investors also form their own opinion of Protalix Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protalix Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protalix Biotherapeutics' market value can be influenced by many factors that don't directly affect Protalix Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protalix Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protalix Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protalix Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.